Fig. 7

Investigations of amplified anti-tumor efficacies by strategic integration of the vasculature-clotting thrombin into prodrug nanomedicine. (a) CLSM images of immunostaining of tumoral blood vessels post systemic treatment (14 days) of a variety of nanomedicine; (b) Quantified vascular densities upon systemic treatment of a variety of nanomedicine (14 days) [n = 4, mean ± s.d., ^***p < 0.001 (student t test)]; (c) Quantification of the red blood cells in tumors by means of quantitative measurement of hemoglobin per tumor (14 days). [n = 4, mean ± s.d., ^**p < 0.01 (student t test)]